Immunalysis Corporation specializes in advanced drug testing technologies, particularly through their proprietary SEFRIA™ and HEIA™ reagents. The SEFRIA™ reagents are noted for their exceptional sensitivity, enabling accurate detection of substances in various testing scenarios. The HEIA™ reagents are designed to adapt to evolving substance abuse trends, ensuring that testing remains reliable and precise. Additionally, Immunalysis offers a comprehensive range of ELISA reagents tailored for forensic testing, reinforcing their commitment to quality and customer satisfaction in the field of drug analysis.

A key innovation from Immunalysis is the Quantisal™ oral fluid collection device, which streamlines the process of drug testing by allowing samples to be collected conveniently and discreetly, without the need for restrooms. This device features a unique volume adequacy indicator that confirms the collection of an adequate specimen, minimizing the risk of insufficient samples. The Quantisal™ device is designed to avoid the use of artificial stimulants, ensuring that drug levels are accurately represented. Furthermore, it provides superior stability for collected specimens, particularly for substances like THC, which can degrade quickly under certain conditions. Overall, Immunalysis Corporation's technologies offer reliable and effective solutions for modern drug testing needs.

United States

Since 1976, Immunalysis Corporation has focused on identifying and meeting the demands of the toxicology marketplace. With an expansive line of ELISA and Homogeneous Enzyme (HEIA™) assays, plus Quantisal™ – Immunalysis' proprietary oral fluid collection device, as well as automation tools and confirmation support, Immunalysis provides forensic toxicologists with powerful, comprehensive drug testing solutions.

Immunalysis Corporation

Company Details